Ann: December 2024 Quarterly Activities Report and Appendix 4C, page-12

DSA - while I don't necessarily disagree with your sentiment and frustrations, I also think shareholders (particularly those that are currently selling) need to take a bit of a deep breath.
The announcement to switch their sales strategy happened during Sept 2024 - almost 5 months ago. Any shareholder that had issues with the Sonic termination and the change of direction re sales strategy would have (should have) long ago left the building. Since the Sept 24 announcement there have been some very positive material announcements and we are closer than ever before to determining whether the new sales strategy will work - yet (some) shareholders still see the need to sell. Further, the short position in PIQ has reduced somewhat to around 582k shares (down from a high of 770k shares) and the ongoing selling is providing the shorts with an easy exit from their shorts.
While the change in strategy did rattle me at first, I always come back to the position that the technology is sound, the products will (should) be in high demand and they will provide significant health and financial benefits to patients and society as a whole. While PIQ and its strategy may not be perfect and I have been critical on some aspects of it, nothing in business occurs in a straight line and ALWAYS takes longer and costs more than thought. If they can nail it then this will be multiples of its current share price so selling now just appears to me to smack of impatience.....but DYOR